Navigation Links
Historic trial for tuberculosis launched together by leading drug companies

Two leading pharmaceutical companies, The Global Alliance for TB Drug Development (TB Alliance) and Bayer Healthcare have announced a partnership to coordinate the study to uncover the potential of an existing antibiotic, //Moxifloxacin, to shorten the standard 6-month treatment of tuberculosis (TB).

Mycobacterium tuberculosis infects one-third of the world's population, resulting in nine million new cases of active TB and two million deaths each year. Current TB therapy involves the use of four drugs discovered forty or more years ago and must be given for six to eight months, under the direct observation of a healthcare provider. A shorter protocol is believed to reduce side effects, improve patient adherence to therapy, and save lives.

The trial would examine the effects of substituting moxifloxacin for one of the standard TB drugs (ethambutol or isoniazid). It is hypothesized that the new drug would eliminate TB infection faster than the existing treatment. In vivo preclinical studies have already shown that the drug significantly reduces treatment time by two months. If the trials are successful, the partnership aims to register moxifloxacin for a TB indication and is committed to making it affordable and accessible in developing countries where there is an utmost needed. The trials would take place in Brazil, Canada, South Africa, Spain, Tanzania, Uganda, the United States and Zambia. Bayer will donate moxifloxacin for each trial site and will cover the costs of regulatory filings. The TB Alliance will coordinate and help cover the costs of the trials. "We are witnessing an historic moment in global health," said Dr. Maria C. Freire, President and CEO of the TB Alliance. "Today, we stand with Bayer, embarking on a major clinical trial program to see if this excellent antibiotic can shorten TB treatment by 2-3 months, which would significantly improve therapy."

"Bayer is committed to working with the TB Alliance to develop a sho rter TB therapy and we are proud to make a tangible contribution and to participate in the movement to achieve the Millennium Development Goal to reverse tuberculosis as a major global health pandemic by 2015." said Dr. Wolfgang Plischke, head of the pharmaceuticals division of Bayer HealthCare.

"This is an important step toward developing a new generation of TB treatments. We urgently need to improve upon current TB drugs, which were developed more than 40 years ago," said Dr. Helene Gayle, Director, HIV, TB and Reproductive Health at the Bill & Melinda Gates Foundation. "By innovating with an existing product, Bayer and the TB Alliance could make an improved TB treatment available much faster than would otherwise be possible."

Related medicine news :

1. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
2. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
3. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
4. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
5. Historic Increase In Incidence Of Sexually Transmitted Diseases In Scotland
6. Black-Owned Hospital Receives Historical Commemorative Marker
7. Man against HIV – new vaccine ready for human trials
8. Male contraceptive in trial
9. How do patients benefit of clinical trials
10. Glenmark’s new molecule to go through trial
11. Clinical trials need to be more frank
Post Your Comments:

(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over ... More than 3.7 billion people under the age of 50 – or 67% of ... WHO's first global estimates of HSV-1 infection . , "The data shocks us highly!" ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... prided itself for not only fulfilling the needs of advisers and clients but ... affordable price and providing top-tier customer service. However, there's always room for improvement, ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
(Date:11/26/2015)... NV (PRWEB) , ... November 26, 2015 , ... Inevitably ... strategy. Many customers choose to buy during the Black Friday and Cyber Monday ... Shoppers don’t need to search the Internet high and low to find the best ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Nov. 29, 2015   Royal Philips  (NYSE: PHG, ... solutions at the 2015 Radiological Society of North America ... McCormick Place in Chicago . Visitors ... the company,s broad portfolio of integrated Diagnostic Imaging, Clinical ... increase clinical performance, improve workflow and create a superior ...
(Date:11/29/2015)...  The GE Health Cloud 1 was unveiled today ... North America (RSNA) meeting in ... new cloud ecosystem and its applications will connect radiologists and ... multidisciplinary teams – both inside and outside the hospital setting. ... GE. "As the digital industrial leader, we are betting big ...
(Date:11/29/2015)... , Nov. 29, 2015   National Decision ... of its client base, including notable statewide implementations. ... company,s flagship solution, ACR Select, more than 1 ... order entry workflow. ACR Select provides real-time feedback ... patient,s condition and has been implemented at over ...
Breaking Medicine Technology: